Reference Detail

Ref Type
PMID
Authors Yihebali Chi, Yongkun Sun, Jianqiang Cai, Yang Yao, Xiaonan Hong, Zhiwei Fang, Ping Sun, Guowen Wang, Qiong Wu, Guofan Qu, Shusen Wang, Jianmin Song, Jianchun Yu, Yongkui Lu, Xia Zhu, Xiaohui Niu, Zhiyong He
Title Phase II study of anlotinib for treatment of advanced soft tissues sarcomas.
Journal J Clin Oncol
Vol
Issue
Date
URL http://meetinglibrary.asco.org/content/167465-176
Abstract Text J Clin Oncol 34, 2016 (suppl; abstr 11005)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown fibrous histiocytoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) treatment resulted a 12-week progression-free rate of 58%, median progression-free survival of 4.1 months, an objective response rate of 5.3% (n=18), and a median overall survival of 11 months in patients with undifferentiated pleomorphic sarcoma (PMID: 29895706; NCT01878448). detail... 29895706
Unknown unknown fibrosarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) treatment resulted a 12-week progression-free rate of 81%, median progression-free survival of 5.6 months, an objective response rate of 11% (n=18), and a median overall survival of 12 months in patients with fibrosarcoma (PMID: 29895706; NCT01878448). detail... 29895706
Unknown unknown liposarcoma not applicable Anlotinib Phase II Actionable In a Phase II trial, Anlotinib (AL-3818) treatment resulted a 12-week progression-free rate of 63%, median progression-free survival of 5.6 months, an objective response rate of 7.7% (n=13), and a median overall survival of 13 months in patients with liposarcoma (PMID: 29895706; NCT01878448). detail... 29895706